Anthropic’s recent purchase of one-man firm Mithril is just the tip of the spear in how it hopes to use AI to accelerate drug development as it seeks a $1.4 trillion valuation in the public markets.
Anthropic’s Drug Discovery Dreams: ‘It Is Not A Side Effort’
FO
Forbes BusinessBy Amy Feldman, Forbes Staff
EXECUTIVE SUMMARY
Anthropic’s recent purchase of one-man firm Mithril is just the tip of the spear in how it hopes to use AI to accelerate drug development as it seeks a $1.4 trillion valuation in the public markets.
Key Takeaways
- Anthropic’s Drug Discovery Dreams: ‘It Is Not A Side Effort’.
- Anthropic’s recent purchase of one-man firm Mithril is just the tip of the spear in how it hopes to use AI to accelerate drug development as it seeks a $1.4 trillion valuation in the public markets.
- Anthropic’s recent purchase of one-man firm Mithril is just the tip of the spear in how it hopes to use AI to accelerate drug development as it seeks a $1.4 trillion valuation in the public markets.
Read Complete Original Article
Published originally on Forbes Business
